Genomics and epidemiology for gastric adenocarcinomas

Abstract

Whereas the pathological aspects of Gastric Adenocarcinomas (GACs) have been well defined, the actual knowledge of its genesis and evolution remains to be translated to better diagnosis and to more effective therapeutics. As a consequence, the current treatment modalities are not yet able to modify the natural history of the disease, which still presents high mortality-rates worldwide. In this review we highlight the current status of relevant epidemiologic, therapeutic and genomics aspects of GACs and point to some of the current knowledge gaps that, if fully addressed, could contribute to a more effective treatment and better management of the patients that suffer from this often-lethal disease.

MicroRNA‑539 inhibits the proliferation and migration of gastric cancer cells by targeting SRY‑box 5 gene

“…A report revealed that the region with the highest incidence of gastric cancer is East Asia, particularly China, with an annual incidence of approximately 4–6 cases per 10,000 individuals (3). In addition, the National Cancer Institute data indicated that the incidence and diagnosis of this disease is mainly between the ages of 60–70 years, and the majority of patients have a poor prognosis due to diagnosis in the late stages of the disease (4). Approximately 90% of stomach tumors are adenocarcinomas, which are classified into two main histologic types: High differentiated or intestinal-type gastric cancer; and undifferentiated or diffuse-type gastric cancer.…”